[go: up one dir, main page]

AR059172A1 - Inhibidores triciclicos de la 5-lipoxigenasa - Google Patents

Inhibidores triciclicos de la 5-lipoxigenasa

Info

Publication number
AR059172A1
AR059172A1 ARP070100298A ARP070100298A AR059172A1 AR 059172 A1 AR059172 A1 AR 059172A1 AR P070100298 A ARP070100298 A AR P070100298A AR P070100298 A ARP070100298 A AR P070100298A AR 059172 A1 AR059172 A1 AR 059172A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
cycloalkyl
group selected
alkenyl
Prior art date
Application number
ARP070100298A
Other languages
English (en)
Original Assignee
Amira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amira Pharmaceuticals Inc filed Critical Amira Pharmaceuticals Inc
Publication of AR059172A1 publication Critical patent/AR059172A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Composiciones farmacéuticas que contienen a dichos compuestos, que inhiben la actividad de la 5-lipoxigenasa (5-LO). Y usos para tratar afecciones, enfermedades o trastornos respiratorios, cardiovasculares, y otras afecciones, enfermedades o trastornos dependientes de leucotrienos o mediados por leucotrienos. Reivindicacion 1: Un compuesto que posee una estructura representada por la formula (2): donde G1 es N o CR1; G4 es N o CR1; cada R1 es independientemente H, haluro, -CN, -NO2, - OH, -OR3,-SR3, -S(=O)R3, -S(=O)2R3, -C(=O)R3, -C(=O)OR3, -CH(R3)2, -N(R3)2, -NHCH2C(=O)OR3, -C(=O)N(R3)2, -NHC(=O)R3, o -C(OH)(R3)2, o un grupo opcionalmente sustituido seleccionado entre alquilo C1-6, fluoralquilo C1-6, cicloalquilo C3-8, alquenilo C2-6, alquinilo C2-6, y fluoralcoxi C1-6; o R1 es Q1-Q2, en donde Q1 es arilo, heterocicloalquilo monocíclico, heteroarilo monocíclico, heteroarilo bicíclico; y Q2 es H, haluro, -CN, -NO2, alquilo C1-6, alcoxi C1-6, -OR3, -SR3, -S(=O)R3, -S(=O)2R3, - C(=O)R3, -C(=O)OR3, -CH(R3)2, -N(R3)2, o -C(=O)N(R3)2; cada R3 es independientemente H, o un grupo opcionalmente sustituido seleccionado entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, fenilo, bencilo, tienilo, furanilo, tiazolilo, piridilo, oxazolilo, oxadiazolilo, tiadiazolilo, imidazolilo, triazolilo, tetrazolilo, piridonilo, y pirimidinilo; L1 es -(CHR4)nX1(CHR4)n- en donde, cada n es independientemente 0, 1, 2, o 3; X1 es un enlace, O, S, S(=O), S(=O)2, o NR5; cada R4 es independientemente H, o un grupo opcionalmente sustituido seleccionado entre alquilo C1-6, cicloalquilo C3-8, fluoralquilo C1-6, alquenilo C2-6, alquinilo C2-6, fenilo, y bencilo; o L4-X2-L5-X3 en donde, L4 es un enlace, o un grupo opcionalmente sustituido seleccionado entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heterocicloalquilo C2-10, y cicloalquilo C3-8; X2 es un enlace, O, S, S(=O), S(=O)2, NH, C(=O)NH, o NHC(=O); L5 es un enlace, alquilo C1-6, cicloalquilo C3-8, fenilo, piridilo, tiazolilo, o tienilo; y X3 es -OH, -CN, -NO2, haluro, -CO2H, -CO2R10, -C(=O)R10, -CON(R10)2, -NHC(=O)R10, C(OH)(R10)2, tetrazolilo, -C(=O)NHSO2R10, -CH(OH)CF3, -COCF3, SO2NHC(=O)R10, o -N(R10)2, en donde cada R10 es independientemente H, o un grupo opcionalmente sustituido seleccionado entre alquilo C1-6, fluoralquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, fenilo, y bencilo; R5 es H, o un grupo opcionalmente sustituido seleccionado entre alquilo C1-6, cicloalquilo C3-8, fluoralquilo C1-6, alquenilo C2-6, alquinilo C2-6, fenilo, y bencilo; o R5 es L6-X5-L7-X6 en donde, L6 es un grupo opcionalmente sustituido seleccionado entre alquilo C1-6, heterocicloalquilo C2-10, y cicloalquilo C3- 8; X5 es un enlace, O, S, S(=O), S(=O)2, NH, C(=O)NH, o NHC(=O); L7 es un enlace, alquilo C1-6, cicloalquilo C3-8, fenilo, piridilo, tiazolilo, o tienilo; y X6 es -OH, -CN, -NO2, haluro, -CO2H, -CO2R10, -C(=O)R10, -C(OH)(R10)2, tetrazolilo, C(=O)NHSO2R10, -CH(OH)CF3, -COCF3, -SO2NHC(=O)R10, o -N(R10)2, donde cada R10 es independientemente H, o un grupo opcionalmente sustituido seleccionado entre alquilo C1-6, fluoralquilo C1-6, alquenilo C2-6 alquinilo C2-6,cicloalquilo C3-8, fenilo, y bencilo; L2 es un grupo opcionalmente sustituido seleccionado entre alquilo C1-6, arilo, heteroarilo monocíclico, y heteroarilo bicíclico; R6 y R7 son independientemente H, o un grupo opcionalmente sustituido seleccionado entre haloalquilo C1-6, alquilo C1-6, cicloalquilo C3-8, alquenilo C2-6, alquinilo C2-6, fenilo, bencilo, tiazolilo, alcoxi C1-6, tioalcoxi C1-6, y alquilo C1-6-X4, en donde, X4 es -CO2H, -CO2R11, -C(=O)R11, -C(OH)(R11)2, alcoxi C1-6, tetrazolilo, -OH, haluro, -CN, -NO2, SR11, -S(=O)R11, -S(=O)2R11, -N(R11)2, -CON(R11)2, -NHC(=O)R11, -C(=O)NHSO2R11, -CH(OH)CF3, -COCF3, o -SO2NHC(=O)R11, en donde cada R11 es independientemente H, o un grupo opcionalmente sustituido seleccionado entre alquilo C1-6, fluoralquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, fenilo, y bencilo; o R6y R7 pueden formar juntos un anillo monocíclico no aromático de 5, 6 o 7 miembros opcionalmente sustituido que contiene 0, 1, o 2 heteroátomos seleccionados entre S y O; o R6 y R7 pueden formar juntos un anillo biciclo [3,2,1] opcionalmente sustituido que contiene 1 o 2 heteroátomos seleccionados entre S y O; o R6 y R7 pueden formar juntos un carbonilo (C=O); y R8 es H, -OH, -CONH2, tetrazolilo, -CN, -N3, alquilo C1-6, alquenilo C2-6, -CF3, -CO2H, -OR12, -CON(R12)2 -CO2-R12, -SR12, -S(=O)R12, S(=O)2R12, -SO2N(R12)2, C(=O)R12, C(OH)(R12)2, -CH=N-OR12, -N(R12)2, NHC(=O)R12, -OC(=O)R12, o un grupo opcionalmente sustituido seleccionado entre fluoralcoxi C1-6, cicloalcoxi C3-8, bencilo, y fenilo; en donde cada R12 es independientemente H, o un grupo opcionalmente sustituido seleccionado entre alquilo C1-6, fluoralquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquilalquilo C4-8, fenilo, y bencilo; o R6 y R8 pueden formar juntos un heterocicloalquilo C2-8 opcionalmente sustituido que posee 1 o 2 átomos de O en el anillo; R9 es H, haluro, -CN, -NO2 -OH, o un grupo opcionalmente sustituido seleccionado entre alquilo C1-6, cicloalquilo C3-8, fluoralquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, fenilo, y bencilo; o R9 es L8-X7-L9-X8, en donde L8 es un enlace, o un grupo opcionalmente sustituido seleccionado entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo, heterocicloalquilo C2-10 o cicloalquilo C3-8; X7 es un enlace, O, S, S(=O), S(=O)2, NH, C(=O)NH, o NHC(=O); L9 es un enlace, alquilo C1-6, cicloalquilo C3-8, fenilo, piridilo, tiazolilo, o tienilo; y X8 es H, -OH, -CN, -NO2, haluro, -CO2H, - CO2R18, -C(=O)R16, -C(OH)(R16)2, -C(=O)N(R16)2, -NHC(=O)R16, tetrazolilo, -C(O)NHSO2R16, -CH(OH)CF3, -COCF3, -SO2NHC(=O)R16, o -N(R16)2, en donde cada R16 es independientemente H, o un grupo opcionalmente sustituido seleccionado entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, fenilo, bencilo, tienilo, furanilo, tiazolilo, piridilo, oxazolilo, oxadiazolilo, tiadiazolilo, imidazolilo, triazolilo, tetrazolilo, piridonilo, y pirimidinilo; o una sal farmacéuticamente aceptable, N-oxido farmacéuticamente aceptable, metabolito farmacéuticamente activo, profármaco farmacéuticamente aceptable, o un solvato farmacéuticamente aceptable del mismo.
ARP070100298A 2006-01-23 2007-01-23 Inhibidores triciclicos de la 5-lipoxigenasa AR059172A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76121706P 2006-01-23 2006-01-23

Publications (1)

Publication Number Publication Date
AR059172A1 true AR059172A1 (es) 2008-03-12

Family

ID=38309772

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100298A AR059172A1 (es) 2006-01-23 2007-01-23 Inhibidores triciclicos de la 5-lipoxigenasa

Country Status (8)

Country Link
US (2) US7919621B2 (es)
EP (1) EP1978966A4 (es)
JP (1) JP2009523820A (es)
AR (1) AR059172A1 (es)
CA (1) CA2636043A1 (es)
MX (1) MX2008009475A (es)
TW (1) TW200738710A (es)
WO (1) WO2007087250A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008009475A (es) * 2006-01-23 2008-10-20 Amira Pharmaceuticals Inc Inhibidores triciclicos de 5-lipoxigenasa.
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
FR2921927B1 (fr) * 2007-10-03 2012-10-12 Univ De Montpellier 1 Imidazo°1,2-a!quinoxalines et derives pour le traitement des cancers
CN101918392A (zh) * 2007-11-26 2010-12-15 辉瑞有限公司 作为5-lo抑制剂的吡唑衍生物
TWI496779B (zh) * 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
US8987251B2 (en) 2008-08-19 2015-03-24 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
US8895550B2 (en) 2008-08-19 2014-11-25 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
WO2010022081A1 (en) * 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
WO2010028388A1 (en) * 2008-09-05 2010-03-11 Solulink Biosciences, Inc. Methods and compositions for direct detection of dna damage
US8669289B2 (en) 2009-04-24 2014-03-11 The Jackson Laboratory Methods and compositions relating to hematologic malignancies
US20120093922A1 (en) 2009-04-29 2012-04-19 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP2462128B1 (en) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
EA024967B1 (ru) 2010-12-07 2016-11-30 Амира Фармасьютикалс, Инк. Полициклический lpaантагонист и его применение
JP2014508111A (ja) 2010-12-07 2014-04-03 アミラ ファーマシューティカルス，インコーポレーテッド リゾフォスファチジン酸受容体アンタゴニスト、その線維症の治療における使用
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
CN103492377B (zh) 2011-02-25 2016-04-20 阵列生物制药公司 作为pim激酶抑制剂的三唑并吡啶化合物
WO2012138797A1 (en) 2011-04-05 2012-10-11 Amira Pharmaceuticals, Inc. 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
US20150322049A1 (en) * 2012-12-13 2015-11-12 Ludwig Aigner Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease
FR3031105B1 (fr) 2014-12-31 2018-04-06 Universite De Montpellier Nouveaux imidazo[1,2-a]quinoxalines et derives pour le traitement des cancers
KR102594441B1 (ko) 2015-03-06 2023-10-25 파마케아, 인크. 플루오르화된 리실 옥시다아제-유사 2 억제제 및 이의 용도
WO2018048943A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
BR112019004513A2 (pt) 2016-09-07 2019-06-18 Pharmakea Inc usos de um inibidor de lisil oxidase-like 2
KR102698385B1 (ko) 2017-07-14 2024-08-22 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
TWI811400B (zh) 2018-07-20 2023-08-11 德商歌林達有限公司 經進一步取代之三唑并喹噁啉衍生物
JP7570399B2 (ja) * 2019-07-18 2024-10-21 ブリストル－マイヤーズ スクイブ カンパニー Ｉｒａｋ４阻害剤として有用な三環式ヘテロアリール化合物
AU2020333225A1 (en) * 2019-08-16 2022-02-24 Cyclacel Limited Process for the preparation of a pyrimidino-diazepine derivative

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787536A (fr) * 1971-08-16 1973-02-14 Lilly Co Eli Agents de lutte contre les organismes phytopathogenes
IT1052009B (it) * 1975-12-30 1981-06-20 Erba Carlo Spa Imidazo 4.3 c 1.4 benzossazino imidazo 4.3 c 1.4 benzotiazino pirazo 2.1 c 1.4 benzossazino e pirazo 2.1 c 1.4 benzotiazino derivati
US4075343A (en) * 1976-09-13 1978-02-21 Pfizer Inc. Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof
US4415679A (en) 1981-10-26 1983-11-15 E. I. Du Pont De Nemours & Co. Process for esterifying fluorinated carboxylic acid polymer
GB8422918D0 (en) * 1984-09-11 1984-10-17 May & Baker Ltd Compositions of matter
DK476885D0 (da) * 1985-10-17 1985-10-17 Ferrosan As Heterocycliske forbindelser og fremgangsmaader til fremstilling heraf
US5002941A (en) * 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
DK160876C (da) * 1987-12-08 1991-10-14 Novo Nordisk As Imidazoquinoxalinforbindelser, fremgangsmaade til deres fremstilling, anvendelse af forbindelserne og farmaceutiske praeparater, hvori forbindelserne indgaar
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5166343A (en) * 1988-02-05 1992-11-24 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimido[1,4]-azines as bronchodilators
US5217977A (en) 1989-02-28 1993-06-08 Imperial Chemical Industries Plc Heterocyclic cycloalkanes
IL93343A0 (en) * 1989-02-28 1990-11-29 Ici Plc Heterocyclic cycloalkanes
JPH02270872A (ja) * 1989-04-11 1990-11-05 Ube Ind Ltd ピロロ〔２，３―ｆ〕キノリンキノン化合物およびその用途
IE911919A1 (en) * 1990-06-21 1992-01-01 Zeneca Ltd Bicyclic heterocyclic compounds
WO1993016082A1 (en) * 1992-02-13 1993-08-19 The Upjohn Company 4-oxo- and 4h-imidazo(5,1-c)(1,4)benzoxazines useful as benzodiazepine receptor-binding agents
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5354865A (en) 1992-09-10 1994-10-11 Abbott Laboratories Phenylmethyl derivatives having lipoxygenase inhibitory activity
AP9400632A0 (en) 1993-04-29 1995-10-07 Zeneca Ltd Ether derivatives.
US5346914A (en) * 1993-05-14 1994-09-13 Abbott Laboratories (4-alkoxypyran-4-yl) substituted arylalkylaryl-, arylalkenylaryl-, and arylalkynylarylurea inhibitors of 5-lipoxygenase
US5424320A (en) 1993-06-23 1995-06-13 Merck Frosst Canada, Inc. Heteroaryl coumarins as inhibitors of leukotriene biosynthesis
US5459271A (en) 1993-07-20 1995-10-17 Merck Frosst Canada, Inc. Arylbicyclooctanes as inhibitors of leukotriene biosynthesis
US5484786A (en) 1993-08-24 1996-01-16 Abbott Laboratories Pyran-4-ylmethyl substituted arylalkylaryl-, arylalkenylylaryl-, and arylalkynylarylurea inhibitors of 5-lipoxygenase
US5407959A (en) 1993-11-12 1995-04-18 Abbott Laboratories (Trans-1,4-dialkoxycyclohexyl) substituted arylalkylaryl-arylalkenylaryl-, and arylalkynylarylurea inhibitors of 5-lipoxygenase
US5475009A (en) 1994-09-12 1995-12-12 Abbott Laboratories 1, 2-dialkoxyethanes as 5-lipoxygenase inhibitors
CN1046518C (zh) * 1994-09-30 1999-11-17 巴斯福股份公司 新型的带杂环取代基的咪唑并喹喔啉酮及其制备方法和应用
US5552437A (en) 1994-10-27 1996-09-03 Merck Frosst Canada, Inc. Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis
US5527827A (en) 1994-10-27 1996-06-18 Merck Frosst Canada, Inc. Bisarylcarbinol cinnamic acids as inhibitors of leukotriene biosynthesis
US5426111A (en) 1994-11-23 1995-06-20 Abbott Laboratories [Alkoxy-, alkenyloxy-, alkynyloxy-, and phenylmethyloxyalkoxycycloalkyl or alkoxycycloheteroalkyl]naphtho[2,3-c]furan-1(3H)-one inhibitors of 5-lipoxygenase
US5576338A (en) 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
ZA968661B (en) * 1995-11-17 1998-04-14 Upjohn Co Oxazolidinone antibacterial agent with tricyclic substituents.
US6451796B1 (en) * 1997-11-11 2002-09-17 Ono Pharmaceutical Co., Ltd. Fused pyrazine compounds
WO2002024683A1 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives
BRPI0408256A (pt) * 2003-03-14 2006-03-01 Astrazeneca Ab composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo
EP1613629A1 (en) * 2003-03-27 2006-01-11 Pfizer Products Inc. Substituted 4-amino 1,2,4 triazolo 4,3-a quinoxalines
WO2004108720A1 (en) 2003-06-11 2004-12-16 Merck Frosst Canada Ltd. 7- (1, 3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors
WO2005030774A1 (en) 2003-09-26 2005-04-07 Rigel Pharmaceuticals, Inc. Hcv inhibitors and methods of using them
PE20060653A1 (es) * 2004-08-31 2006-09-27 Glaxo Group Ltd Derivados triciclicos condensados como moduladores del receptor 5-ht1
MX2008009475A (es) * 2006-01-23 2008-10-20 Amira Pharmaceuticals Inc Inhibidores triciclicos de 5-lipoxigenasa.

Also Published As

Publication number Publication date
EP1978966A2 (en) 2008-10-15
US20110112106A1 (en) 2011-05-12
US20070173508A1 (en) 2007-07-26
CA2636043A1 (en) 2007-08-02
TW200738710A (en) 2007-10-16
WO2007087250A2 (en) 2007-08-02
EP1978966A4 (en) 2010-11-10
MX2008009475A (es) 2008-10-20
US7919621B2 (en) 2011-04-05
WO2007087250A3 (en) 2008-01-31
JP2009523820A (ja) 2009-06-25

Similar Documents

Publication Publication Date Title
AR059172A1 (es) Inhibidores triciclicos de la 5-lipoxigenasa
CA2903288C (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
JP5977347B2 (ja) Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体
JP6160613B2 (ja) Ｔｒｋ阻害化合物
US20250129060A1 (en) Solid forms of an sgc stimulator
PH12015502114B1 (en) 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
US10450288B2 (en) Hydroxy formamide derivatives and their use
EA201391158A1 (ru) Диаминиевые соли фенотиазина и их применение
JP2003335776A (ja) 二環性化合物、その製造法および用途
JP2016503009A5 (es)
WO2012101065A3 (en) Pyrimidine biaryl amine compounds and their use as cdk9 inhibitors
AR078321A1 (es) Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9)
WO2003090748A1 (fr) Utilisation de composes a antagonisme anti-ccr
KR20240027769A (ko) Mnk 억제를 나타내는 스피로사이클릭 피리딘-1,5-디온 및 이의 사용 방법
JP2015502371A5 (es)
AR057849A1 (es) Dialurrea para el tratamiento de hipertension pulmonar
JP2009040767A5 (es)
US10143681B2 (en) Factor XIa inhibitors
JP2013523739A5 (es)
EA201391314A1 (ru) Новое фенилпиридиновое производное и содержащее его лекарственное средство
JP2004256531A (ja) 三環性化合物、その製造法および用途
AU2021409234A1 (en) Preparation of tetrahydroindazole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors
US20180362485A1 (en) N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP l, TLL1 AND/OR TLL2 INHIBITORS
CN103958484A (zh) 噁唑烷酮类衍生物、其制备方法及其在医药上的应用
JP2010519208A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure